We join forces with large companies with the purpose of providing solutions to the challenges of Barcelona

Ferrer and Prilenia Announce Start of PRECISE-HD Confirmatory Clinical Trial of Pridopidine in Huntington's Disease

First participant in Europe in the Phase 3 clinical trial "PREVAiLS" with pridopidine, in ALS

IMPAHCT celebrates its eighth edition by reinforcing the comprehensive approach to rare lung diseases

Ferrer and Prilenia Announce Inclusion of First Participant in Phase 3 Clinical Trial "PREVAiLS" with Pridopidine, in ALS

Ferrer included in the ranking of the most ethical companies in the world in 2026

We join forces with large companies in Barcelona to stop school dropout

Ferrer Spain promotes the foundations of a new value-based public procurement model

We completed the recruitment of 220 patients for PROSPER, the Phase II clinical trial in progressive supranuclear palsy

Nature Medicine publishes phase 3 data on pridopidine in early-stage Huntington's disease

Prilenia and Ferrer report on the European regulatory process for pridopidine for Huntington's disease

Ferrer reinforces its impact in 2024 with more social and environmental investment, B Corp leadership and advances in sustainability